Lenalidomide is safe and active in Waldenström macroglobulinemia
- 6 October 2015
- journal article
- research article
- Published by Wiley in American Journal of Hematology
- Vol. 90 (11), 1055-1059
- https://doi.org/10.1002/ajh.24175
Abstract
Purpose. Lenalidomide is manageable and effective in Multiple Myeloma, particularly in elderly patients. Surprisingly, the combination of lenalidomide with rituximab produced clinically significant anemia at 25mg/day for 21/28 days, the highest possible dose, in Waldenström's Macroglobulinemia (WM). We aimed to determine the maximum tolerated dose (MTD) of single agent lenalidomide and determine its impact on WM. Materials and methods. RV‐WM‐0426 is a multicenter dose escalation open label phase 1/2 study of lenalidomide in relapsed/refractory WM (RRWM). Lenalidomide was given orally 21/28 days per cycle for one year, at escalated dose of 15 to 20 mg during phase 1 to determine the MTD; the phase 2 part was conducted at the MTD. Results. 17 RRWM patients were included. The MTD was established at 15 mg/day 21/28. By ITT analysis, the overall response rate was 29%. With a median follow‐up of 36 months, median TTP was 16 months (95%CI 5.5‐26), the 5‐year OS was 91%. The most frequent AE ≥ grade 3 at 15mg were 14% anemia and 43% neutropenia. Conclusion. The MTD of lenalidomide is 15mg/day 21/28 days in RRWM. Lenalidomide is active in the treatment of RRWM and the safety profile appears manageable. Future studies may look into combinations of lenalidomide and continuous dosing.Keywords
Funding Information
- Celgene
This publication has 22 references indexed in Scilit:
- Lenalidomide and Dexamethasone in Transplant-Ineligible Patients with MyelomaThe New England Journal of Medicine, 2014
- Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensusBlood, 2014
- Results of a Randomized Trial of Chlorambucil Versus Fludarabine for Patients With Untreated Waldenström Macroglobulinemia, Marginal Zone Lymphoma, or Lymphoplasmacytic LymphomaJournal of Clinical Oncology, 2013
- Response assessment in Waldenström macroglobulinaemia: update from the VIth International WorkshopBritish Journal of Haematology, 2012
- Lenalidomide and Rituximab in Waldenstrom's MacroglobulinemiaClinical Cancer Research, 2008
- Thalidomide and rituximab in Waldenstrom macroglobulinemiaBlood, 2008
- Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor CellsClinical Cancer Research, 2008
- Molecular mechanisms whereby immunomodulatory drugs activate natural killer cells: clinical applicationBritish Journal of Haematology, 2004
- Clinicopathological definition of Waldenstrom's macroglobulinemia: Consensus Panel Recommendations from the Second International Workshop on Waldenstrom's MacroglobulinemiaSeminars in Oncology, 2003
- Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myelomaBlood, 2001